Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed invasive breast cancer~  * First local and/or regional (i.e., ipsilateral axillary or internal mammary lymph node region) recurrence after primary treatment with mastectomy or lumpectomy/quadrantectomy with clear surgical margins~    * Local failure is defined as a tumor recurrence in any soft tissue of the ipsilateral conserved breast or the chest wall, mastectomy scar, and/or skin~   * Regional failure is defined as a tumor recurrence in the ipsilateral axillary lymph nodes, extranodal soft tissue of the ipsilateral axilla, and/or ipsilateral internal mammary. Regional failure does not include supraclavicular lymph nodes or tumor in the opposite breast~ * No other prior recurrence in any site, including local~* Surgical resection of the recurrence meeting 1 of the following criteria:~  * Uninvolved (clear) margins and planned radiotherapy with at least 40 Gy for patients who had no prior adjuvant radiotherapy~ * Mastectomy of the recurrence with uninvolved (clear) margins after lumpectomy/quadrantectomy alone for the primary~* Adjuvant trastuzumab (Herceptin®) therapy or other HER-2 directed therapies are allowed for patients with HER-2 positive tumors and must be declared prior to randomization~* No evidence of distant metastasis, including ipsilateral supraclavicular lymph nodes, by x-ray or CT scan of the chest, ultrasound or CT scan of the abdomen and pelvis, or bone scintigraphy only if alkaline phosphatase is \> 2 times normal or if medically indicated (e.g., bone pain)~* No macroscopically incomplete surgery~* No bilateral malignancy except carcinoma in situ~* No suspicious mass in the opposite breast unless that mass has been proven by biopsy to be benign~* No skeletal pain of unknown cause~  * No hot spots on bone scan for which metastases cannot be ruled out by x-ray, MRI, and/or CT scan~* Hormone receptor status:~  * Determined in the recurrent tumor by immunohistochemistry and/or ligand-binding assay~ * Estrogen receptor positive or negative~ * Progesterone receptor positive or negative~PATIENT CHARACTERISTICS:~Age~* Minimum 18 years~Sex~* Female~Menopausal status~* Not specified~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* No elevated alkaline phosphatase~Renal~* Not specified~Other~* Fertile patients must use effective non-hormonal contraception~* Medically suitable for chemotherapy of 3-6 months duration~* No other primary malignant tumors except adequately treated carcinoma in situ of the cervix or nonmelanoma skin cancer~* No non-malignant systemic disease that would preclude study treatment or prolong follow-up~* No psychiatric or addictive disorder that would preclude giving informed consent~* No history of noncompliance to medical regimens or potential for being unreliable~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~Surgery~* See Disease Characteristics

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients receive radiotherapy\* within 6 months after surgery.
- Arm II (Type: EXPERIMENTAL): Within 10 weeks after surgery, patients receive at least 3 courses of an adjuvant chemotherapy regimen as determined by the investigator. Patients may receive radiotherapy within 6 months after surgery and after the completion of chemotherapy OR integrated with chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).